The drug was approved by the US FDA in June 2021 as a 2.4 mg once-weekly injection for chronic weight management in adults with obesity or those overweight with at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.3 In 2023, according to market information from Midas (IQVIA), sales of semaglutide for weight management more than quadrupled year-on-year, and further interest has been spurred by new indications related to reducing cardiovascular risk, and emerging benefits are being shown in people with Alzheimers disease.4,5 The strength of these figures clearly demonstrates the intense demand for GLP-1 treatments, but it does not convey the unforeseen implications of such high levels of popularity
Whereas it is unlikely that the topical preparation as such immediately and directly reaches the hair bulb region, it has been shown that drug delivery to the skin occurs also through the hair follicles [32]
At the same time, pharmaceutical companies have faced increasing public and regulatory pressure to lower self-pay (cash) prices for these medications though pricing and discount programs vary by drug and pharmacy
You're already on tirzepatide and it's working, so should you switch to retatrutide
This visit includes a full provider evaluation, InBody body composition scan, symptom review, and protocol design
| Hebei Huarong Pharmaceutical Co., Ltd
